Valentis was founded by a team of pharmaceutical professionals with deep industry experience and a shared vision to create value in healthcare.
Valentis was founded by a team of pharmaceutical professionals with deep industry experience and a shared vision to create value in healthcare.
Expanded into niche markets, focusing on disease awareness programs and introducing medical devices designed to improve quality of life for patients.
Valentis Health Services was established to strengthen patient engagement through targeted awareness programs, particularly in oncology.
Valentis Laboratories obtained a Wholesale Distribution
License (WDL) from the Turkish Ministry of Health,
enabling the company to expand internationally in
pharmaceutical supply.
Gemini Gen and PeraLabs were launched to provide CTC analysis and NGS-based diagnostic services, supporting precision medicine and early detection in oncology.
Valentis CTS was founded to support clinical research by supplying comparator drugs and reference products for R&D and clinical trials globally.
International expansion milestones achieved with the opening of:
▪ Valentis CTS GmbH (Germany)
▪ Valentis CTS AG (Switzerland)
▪ Valentis CTS LLC-FZ (Dubai, UAE)
Valentis CTS GmbH was granted a Wholesale Distribution Authorization (WDA) in Germany, marking a key step in expanding our footprint across Europe.